Monday’s earnings reports show strong demand for hotel stays, beauty products and veterinary diagnostics, alongside sharply higher optical-component sales. Insurance delivered a tougher quarter, with reserve charges weighing on profits, while utility reports highlighted the difference between underlying operating earnings and reported net income.
In Simple Words
Revenue tells you how much a company sold, while earnings show what remained after expenses. Adjusted earnings remove selected items, so they should be compared with adjusted estimates rather than mixed with reported profit.
All financial figures below are in US dollars. Year-ago comparisons refer to the corresponding quarter.
Marriott International: Stronger bookings lift the annual outlook
Marriott’s third-quarter performance benefited from higher room rates and occupancy, with the US and Canada delivering particularly strong growth. Adjusted earnings beat expectations, and management raised its full-year forecast for revenue per available room.
Also Read: US Stocks to Watch Today, November 2, 2026: Apple, Marvell, Palantir and Fresh Deal Catalysts
| Measure | Reported | Comparison or guidance |
|---|---|---|
| Total revenue | $7.005 billion | $6.489 billion year-ago |
| Adjusted diluted EPS | $3.02 | $2.84 estimated; $2.47 year-ago |
| GAAP diluted EPS | $3.04 | $2.67 year-ago |
| Net income | $794 million | $728 million year-ago; up 9% |
| Worldwide RevPAR | Up 6.5% | US and Canada growth of 7.4% |
| Full-year RevPAR guidance | Growth of 4.5%–5% | Raised from 3%–3.5% |
Marriott’s total revenue includes reimbursements of costs incurred on behalf of hotel owners.
Estée Lauder: Profit recovery gathers pace
Estée Lauder’s fiscal first-quarter earnings grew much faster than sales, supported by stronger fragrance demand and improved profitability. Management raised its annual sales, margin and adjusted earnings forecasts, extending the recovery beyond the completed quarter.
| Measure | Reported | Comparison or guidance |
|---|---|---|
| Net sales | $3.715 billion | $3.481 billion year-ago; up 7% |
| Adjusted diluted EPS | $0.72 | $0.51 estimated; $0.32 year-ago |
| GAAP diluted EPS | $0.64 | $0.13 year-ago |
| Net earnings | $233 million | $47 million year-ago |
| Full-year adjusted EPS guidance | $3.20–$3.45 | Previously $3.10–$3.35 |
| Full-year organic sales guidance | Growth of 4%–5.5% | Previously 3%–5% |
Fox: Advertising growth drives a substantial earnings increase
Fox’s fiscal first-quarter revenue and earnings rose strongly, with World Cup broadcasts, political advertising and digital growth supporting advertising sales. Television profitability improved sharply, while distribution revenue added another source of growth.
| Measure | Reported | Comparison or guidance |
|---|---|---|
| Revenue | $4.57 billion | Up 22% year-on-year |
| Adjusted EPS | $2.54 | $1.51 year-ago |
| Reported EPS | $2.20 | $1.32 year-ago |
| Net income attributable to shareholders | $943 million | $599 million year-ago |
| Adjusted EBITDA | $1.641 billion | $1.065 billion year-ago |
| Advertising revenue | Up 47% | Distribution revenue increased 9% |
Lumentum: Revenue more than doubles as margins expand
Lumentum’s fiscal first-quarter revenue increased sharply, accompanied by substantial improvements in both reported and adjusted profitability. Its next-quarter forecast points to another sequential increase in sales and adjusted earnings.
Also Read: India Top Earnings Today, November 2, 2026: Marico, UPL, Escorts Kubota, CONCOR and Other Q2 Results
| Measure | Reported | Comparison or guidance |
|---|---|---|
| Revenue | $1.2626 billion | $533.8 million year-ago; up 136.5% |
| Adjusted diluted EPS | $4.57 | $1.10 year-ago |
| GAAP diluted EPS | $3.54 | $0.05 year-ago |
| GAAP net income | $360.3 million | $4.2 million year-ago |
| Next-quarter revenue guidance | $1.575–$1.625 billion | Fiscal second quarter |
| Next-quarter adjusted EPS guidance | $5.90–$6.20 | Non-GAAP diluted basis |
IDEXX Laboratories: Diagnostics growth supports higher guidance
IDEXX delivered double-digit revenue growth, led by recurring companion-animal diagnostics and stronger testing volumes. Earnings increased faster than sales as operating margins expanded, allowing management to raise its annual revenue and EPS outlook.
| Measure | Reported | Comparison or guidance |
|---|---|---|
| Revenue | $1.214 billion | Up 10% reported and organic |
| Diluted EPS | $4.01 | Up 18% reported |
| Net income attributable to shareholders | $317.145 million | $274.610 million year-ago |
| Operating margin | 33.1% | Up 1 percentage point |
| Full-year revenue guidance | $4.741–$4.767 billion | Midpoint raised by $32 million |
| Full-year EPS guidance | $14.96–$15.16 | Midpoint raised by $0.25 |
Tempus AI: Higher revenue and a narrower loss
Tempus increased revenue across diagnostics and data services, with oncology testing volumes and Data & Applications providing momentum. The company narrowed its reported loss substantially and raised its annual sales forecast, although investment gains also supported the bottom line.
| Measure | Reported | Comparison or guidance |
|---|---|---|
| Revenue | $411.5 million | $334.2 million year-ago; up 23% |
| GAAP net loss | $14.9 million | $80.0 million loss year-ago |
| Adjusted EBITDA | $25.6 million | $1.5 million year-ago |
| Unrealised securities gains | $42.8 million | Included in reported results |
| Full-year revenue guidance | $1.600–$1.605 billion | Raised; approximately 25% growth |
| Full-year adjusted EBITDA outlook | Approximately $65 million | Maintained |
Entergy: Higher electricity sales strengthen earnings
Entergy’s quarterly earnings benefited from higher retail electricity sales, including weather effects, alongside regulatory recoveries and returns on utility investment. Higher interest, operating and depreciation expenses absorbed part of those gains, while management narrowed its annual adjusted EPS range.
| Measure | Reported | Comparison or guidance |
|---|---|---|
| Reported EPS | $1.98 | $1.53 year-ago |
| Adjusted EPS | $1.98 | $1.53 year-ago |
| Consolidated earnings | $940 million | $694 million year-ago |
| Utility-business earnings | $1.079 billion | $810 million year-ago |
| Full-year adjusted EPS guidance | $4.35–$4.45 | Range narrowed |
PSEG: Underlying earnings hold up as reported profit falls
PSEG’s operating earnings edged higher, but reported profit declined as investment and mark-to-market losses weighed on its power business. Management maintained the annual operating earnings forecast, with higher nuclear generation and realised prices helping the underlying performance.
Also Read: US Weekly Earnings Review: Microsoft, Alphabet, Amazon, Intel and Major Q3 Results (Oct 26–30, 2026)
| Measure | Reported | Comparison or guidance |
|---|---|---|
| Operating revenue | $3.020 billion | $3.226 billion year-ago |
| GAAP EPS | $0.76 | $1.24 year-ago |
| Non-GAAP operating EPS | $1.15 | $1.13 year-ago |
| Net income | $376 million | $622 million year-ago |
| Non-GAAP operating earnings | $574 million | $565 million year-ago |
| Full-year operating EPS guidance | $4.28–$4.40 | Reaffirmed |
CNA Financial: Reserve charges weigh heavily on profit
CNA’s quarterly profit fell as long-term care reserve updates compounded weaker underlying underwriting results and higher catastrophe losses. Property-and-casualty premiums continued to grow, but that expansion was insufficient to offset the earnings pressure.
| Measure | Reported | Comparison or guidance |
|---|---|---|
| Revenue | $3.821 billion | $3.817 billion year-ago |
| Diluted EPS | $0.72 | $1.48 year-ago |
| Core income per share | $0.75 | $1.50 year-ago |
| Net income | $196 million | $403 million year-ago |
| Long-term care reserve impact | $137 million after tax | Unfavourable quarterly impact |
| Quarterly dividend | $0.48 per share | Payable December 3 |
Loews: Insurance weakness outweighs hotel improvement
Loews reported lower quarterly earnings as its insurance subsidiary’s reserve charges and underwriting pressure outweighed improvements elsewhere. Its hotel business returned to profit, supported by higher room rates and occupied room nights, while consolidated revenue increased modestly.
| Measure | Reported | Comparison or guidance |
|---|---|---|
| Revenue | $4.759 billion | $4.671 billion year-ago |
| EPS | $1.50 | $2.43 year-ago |
| Net income | $306 million | $504 million year-ago |
| Loews Hotels net income | $16 million | $3 million loss year-ago |
| Loews Hotels adjusted EBITDA | $86 million | $69 million year-ago; up 25% |
Krystal Biotech: Product sales rise, but net income declines
Krystal Biotech increased quarterly product revenue substantially while keeping research and development spending broadly steady and reducing selling and administrative expenses. Reported net income and diluted earnings nevertheless declined from the year-earlier quarter.
| Measure | Reported | Comparison or guidance |
|---|---|---|
| Net product revenue | $127.3 million | $97.8 million year-ago |
| Diluted EPS | $2.05 | $2.66 year-ago |
| Net income | $63.1 million | $79.4 million year-ago |
| R&D expense | $14.9 million | $14.6 million year-ago |
| Selling and administrative expense | $33.7 million | $37.6 million year-ago |
| Full-year adjusted R&D and administrative expense guidance | $155–$165 million | Excludes stock-based compensation |
Information Services Group: Modest sales growth produces stronger margins
Information Services Group increased revenue and expanded profitability, with Asia-Pacific growth and recurring revenue supporting the quarter. Operating cash generation strengthened, and both revenue and adjusted EBITDA exceeded the company’s guidance.
Also Read: US Stock Market Weekly Wrap-Up: AI Doubts Pull Wall Street Lower (Oct 26–30, 2026)
| Measure | Reported | Comparison or guidance |
|---|---|---|
| Revenue | $65.1 million | $62.4 million year-ago; up 4.4% |
| GAAP diluted EPS | $0.07 | $0.06 year-ago |
| Adjusted diluted EPS | $0.10 | $0.09 year-ago |
| Net income | $3.4 million | $3.1 million year-ago |
| Adjusted EBITDA | $10.0 million | Up 19% year-on-year |
| Next-quarter guidance | Revenue of $64–$65 million | Adjusted EBITDA of $9–$10 million |
Disclaimer: This article is published for educational and informational purposes only and does not constitute financial, investment or trading advice. OneTrader is not registered with the Securities and Exchange Board of India (SEBI) as an investment adviser or research analyst. The information presented is not a recommendation to buy, sell or hold any security. Market conditions and company developments may change.
Keep learning with OneTrader
Explore structured lessons and practical guides to build your market knowledge.
Need a laugh after all that money talk?
Paisa LOL: India's funniest finance page, with memes, comics, jokes and long funny stories.
